Volume | 630,810 |
|
|||||
News | - | ||||||
Day High | 20.88 | Low High |
|||||
Day Low | 20.10 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Kura Oncology Inc | KURA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
20.78 | 20.10 | 20.88 | 20.545 | 21.07 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
9,958 | 630,810 | $ 20.52 | $ 12,943,743 | - | 7.41 - 24.17 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:29:08 | formt | 101,659 | $ 20.545 | USD |
Kura Oncology Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.56B | 76.14M | - | 0 | -152.63M | -2.00 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Kura Oncology News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KURA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 19.63 | 21.30 | 19.63 | 20.71 | 654,183 | 0.915 | 4.66% |
1 Month | 20.07 | 21.30 | 16.79 | 19.10 | 864,856 | 0.475 | 2.37% |
3 Months | 19.91 | 24.17 | 16.79 | 20.69 | 911,379 | 0.635 | 3.19% |
6 Months | 9.28 | 24.17 | 8.17 | 17.36 | 1,227,415 | 11.27 | 121.39% |
1 Year | 11.37 | 24.17 | 7.41 | 14.67 | 998,694 | 9.18 | 80.69% |
3 Years | 25.93 | 26.41 | 7.41 | 15.10 | 839,335 | -5.39 | -20.77% |
5 Years | 15.62 | 43.00 | 6.34 | 17.75 | 712,205 | 4.93 | 31.53% |
Kura Oncology Description
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. |